Study Name:
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced NON-SMALL CELL LUNG CANCER (LA NSCLC)
Study Dates:
August 20, 2019 - November 30, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Bristol Myers Squibb
Contact:
Name: BMS Study Connect
Phone: 855-907-3286
Email: Clinical.Trials@bms.com
ClinicalTrails.gov Identifier:
NCT04026412
